Sergey M Deyev
Overview
Explore the profile of Sergey M Deyev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belyaev I, Griaznova O, Yaremenko A, Deyev S, Zelepukin I
Adv Drug Deliv Rev
. 2025 Feb;
219:115550.
PMID: 40021012
Delivery of nanoparticles (NPs) to solid tumors has long relied on enhanced permeability and retention (EPR) effect, involving permeation of NPs through a leaky vasculature with prolonged retention by reduced...
2.
Konshina A, Bocharov E, Konovalova E, Schulga A, Tolmachev V, Deyev S, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39518923
Non-immunoglobulin-based scaffold proteins (SPs) represent one of the key therapeutic target-specific and high-affinity binders in modern medicine. Among their cellular targets are signaling receptors, in particular, receptor tyrosine kinases, whose...
3.
Alekseeva N, Boyko A, Shevchenko M, Grechikhina M, Streltsova M, Alekseeva L, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457710
The functional activity of a certain tumor determines the effectiveness of primary NK cells and NK-92 cell line-based cancer therapy; their therapeutic effectiveness against different tumors can vary. This work...
4.
Belyaev I, Mirkasymov A, Rodionov V, Babkova J, Nikitin P, Deyev S, et al.
Biomed Mater
. 2024 Sep;
19(6).
PMID: 39312951
Pharmacokinetics of nanomedicines can be improved by a temporal blockade of mononuclear phagocyte system (MPS) through the interaction with other biocompatible nanoparticles. Liposomes are excellent candidates as blocking agents, but...
5.
Popov A, Kolmanovich D, Chukavin N, Zelepukin I, Tikhonowski G, Pastukhov A, et al.
Molecules
. 2024 Aug;
29(16).
PMID: 39203014
Boron-enhanced proton therapy has recently appeared as a promising approach to increase the efficiency of proton therapy on tumor cells, and this modality can further be improved by the use...
6.
Zelchan R, Chernov V, Medvedeva A, Rybina A, Bragina O, Mishina E, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199590
A high level of EpCAM overexpression in lung cancer makes this protein a promising target for targeted therapy. Radionuclide visualization of EpCAM expression would facilitate the selection of patients potentially...
7.
Zelepukin I, Shevchenko K, Deyev S
Nat Commun
. 2024 May;
15(1):4366.
PMID: 38777821
Rapid uptake of nanoparticles by mononuclear phagocyte system (MPS) significantly hampers their therapeutic efficacy. Temporal MPS blockade is one of the few ways to overcome this barrier - the approach...
8.
Deyev S, Oroujeni M, Garousi J, Graslund T, Li R, Rosly A, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673831
Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting protein binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2...
9.
Belyaev I, Zelepukin I, Kotelnikova P, Tikhonowski G, Popov A, Kapitannikova A, et al.
Adv Sci (Weinh)
. 2024 Mar;
11(20):e2307060.
PMID: 38516744
Biodegradable nanomaterials can significantly improve the safety profile of nanomedicine. Germanium nanoparticles (Ge NPs) with a safe biodegradation pathway are developed as efficient photothermal converters for biomedical applications. Ge NPs...
10.
Alekseeva L, Ovsyanikova O, Schulga A, Grechikhina M, Shustova O, Kovalenko E, et al.
Cells
. 2024 Feb;
13(4.
PMID: 38391930
(1) Background: We have previously shown that the use of an artificial supramolecular two-component system based on chimeric recombinant proteins 4D5scFv-barnase and barstar-heat shock protein 70 KDa (HSP70) allows targeted...